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Abstract Thiazolidinediones (TZDs), potent peroxisome pro-
liferator-activated receptor Q ligands, have been shown to im-
prove endothelial function in vascular diseases. We investigated
the e¡ects of pioglitazone, a TZD, on monocyte^endothelial
interaction under £ow and found that pretreatment (20 Wmol/l,
48 h) signi¢cantly reduced U937 adhesion to human umbilical
vein endothelial cells. Integrin expression was not altered, how-
ever, the activation of RhoA GTPase was signi¢cantly reduced
after treatment. Further, pioglitazone treatment signi¢cantly
reduced phosphorylation of focal adhesion kinase (FAK) at
925Y, but not at 397Y, suggesting a speci¢c role in FAK-de-
pendent signaling. These results indicate a novel anti-in£amma-
tory role for this compound.
8 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Thiazolidinediones (TZDs) are insulin-sensitizing com-
pounds that have been used to treat patients with type 2
diabetes. TZD compounds have been identi¢ed as a ligand
for peroxisome proliferator-activated receptor Q (PPARQ),
which belongs to a nuclear hormone receptor superfamily,
and also received attention for their potential anti-in£amma-
tory e¡ects. Further, PPARQ activators such as 15-deoxy-
12,14-prostaglandin J2, and TZDs have been shown to inhibit
the production of several in£ammatory cytokines, including
interleukin (IL) 1L, IL-6, and tumor necrosis factor K in
monocytes [1], and inducible nitric oxide synthase, matrix
metalloprotease-9, and scavenger receptor-A expression in
macrophages [2], and have also been reported to have anti-
in£ammatory e¡ects that are independent of PPARQ [3]. We
investigated the inhibitory e¡ects of pioglitazone, a TZD, on
monocyte^endothelial interaction under £ow conditions and
examined the molecular consequences.
2. Materials and methods
2.1. Cell culture and reagents
A U937 cell line was obtained from the American Type Culture
Collection (Rockville, MD, USA) and grown in RPMI 1640 medium
supplemented with 10% fetal calf serum (Life Technologies Oriental,
Tokyo, Japan). Human umbilical vein endothelial cells (HUVEC)
were isolated from normal-term umbilical cords and maintained as
previously described [4,5]. Recombinant human IL-1L was obtained
from Genzyme (Cambridge, MA, USA). BCECF-AM and FITC-con-
jugated phalloidin were obtained from Molecular Probes (Eugene,
OR, USA). Pioglitazone hydrochloride was a gift from Takeda Chem-
ical Industry (Osaka, Japan) and was stored as a 20 mmol/l stock
solution in dimethyl sulfoxide. Mouse anti-CD11a monoclonal anti-
body (clone 38, Ancell, Bayport, MN, USA); mouse anti-CD11b
monoclonal antibody (clone 44, YLEM, Avezzano, Italy), mouse
anti-CD18 monoclonal antibody (clone MEM48, Southern Biotech-
nology Associates, Birmingham, AL, USA), and mouse anti-CD49d
monoclonal antibody (clone A4-PUJ1, Upstate Biotechnology, Lake
Placid, NY, USA) were used in the present study. Rho activation
assay kit was obtained from Upstate Biotechnology. Anti-focal adhe-
sion kinase (FAK) monoclonal antibody was obtained from BD Bio-
sciences (Franklin Lakes, NJ, USA). Anti-phosphorylated (p) FAK
(397Y) monoclonal antibody and anti-pFAK (925Y) monoclonal anti-
body were obtained from Biosource (Camarillo, CA, USA). Horse-
radish peroxidase-conjugated goat anti-mouse IgG and anti-rabbit
IgG were obtained from Cal-tag (Burlingame, CA, USA).
2.2. Monocyte adhesion assay
Static adhesion assays were carried out as previously described in
detail [6]. In brief, U937 cells were prelabeled with BCECF-AM for 20
min at 37‡C, and then placed on HUVEC plated in a 96-well micro-
titer culture plate and incubated for 10 min at room temperature. The
£uorescent intensity of the monolayer-associated U937 cells was quan-
titated using a £uorescent plate reader (Perseptive Biosystems). Adhe-
sion assays under laminar £ow were carried out as described previ-
ously [7]. In brief, HUVEC monolayers on coverslips were stimulated
with 10 U/m of IL-1L for 4 h, positioned in the £ow chamber
mounted on an inverted microscope (lU70, Olympus, Tokyo, Japan).
U937 cells (1U106/ml) were drawn through the chamber at a wall
shear stress of 1.0 dyne/cm2 for 10 min. The entire period of perfusion
was recorded using a video tape recorder. The numbers of rolling and
adherent U937 cells on HUVEC monolayer in 6^10 randomly selected
20U microscope ¢elds were determined.
2.3. Filamentous actin content in U937 cells
U937 cells were washed twice with Dulbecco’s Phosphate-Bu¡ered
Saline (DPBS) and ¢xed with 1% paraformaldehyde in DPBS for
5 min, then permeabilized with 0.1% Triton X-100 in DPBS for 60 s.
U937 cells were then incubated with FITC-conjugated phalloidin
(1:100 dilution) in DPBS for 60 min. After washing twice with
DPBS, U937 cells were lysed with 150 Wl of 0.01% NaOH in 0.1%
sodium dodecyl sulfate (SDS) and £uorescent intensity was quanti-
tated using a £uorescent plate reader.
2.4. RhoA translocation in U937 cells
RhoA translocation in U937 cells was examined by Western blot-
ting analysis as described previously [8,9]. In brief, U937 cells were
incubated with pioglitazone and then lysed in 100 Wl of ice-cold lysis
bu¡er (0.1 mol/l Tris^HCl, 0.15 mol/l NaCl, and 5 mmol/l EDTA, pH
7.4) containing 0.1% Triton X-100, 10 Wg/ml leupeptin, 60 U/ml apro-
tinin, 1 mM phenylmethylsulfonyl £uoride, and 100 Wmol/l sodium
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vanadate for 5 min, then centrifuged at 15 000 rpm for 15 min. The
supernatants were collected as the cytosol fractions of the cell lysate.
Pellets were washed with phosphate-bu¡ered saline and lysed for 5 min
in 100 Wl of ice-cold lysis bu¡er as described above, except that it
contained 1% Triton X-100, after which they were centrifuged at
15 000 rpm for 15 min. The supernatants were collected as the mem-
brane fractions. To obtain a total cell lysate, U937 cells were lysed
with 100 Wl of ice-cold lysis bu¡er containing 1% Triton X-100 for 10
min. An equal amount of protein (10 Wg) from each lysate was sub-
jected to 12.5% SDS^polyacrylamide gel electrophoresis and Western
blotting analysis was carried out using mouse anti-RhoA monoclonal
antibody (1:500 dilution). Activation of RhoA was determined by
using a glutathione S-transferase (GST) fusion protein of the Rho
binding domain of the Rho e¡ector Rhotekin (Rho activation assay
kit) following the manufacturer’s protocol.
2.5. FAK phosphorylation in U937 cells
Phosphorylation of FAK at both 925Y and 397Y in U937 cells was
examined by Western blotting analysis using phosphorylation-speci¢c
monoclonal antibodies against FAK as described above.
2.6. Statistical analysis
Results are presented as meanSS.D. Data were analyzed using
analysis of variance. P6 0.05 was considered signi¢cant.
3. Results
3.1. Pioglitazone reduced IL-1L-induced U937 cell adhesion to
HUVEC
We ¢rst examined the e¡ect of pioglitazone on monocytic
U937 adhesion to cytokine-activated HUVEC (IL-1L 10 U/
ml, 4 h). U937 cells were pretreated with various concentra-
tions (1, 5, 10 and 20 Wmol/l) of pioglitazone for 48 h prior to
an adhesion assay. As shown in Fig. 1A, a dose-dependent
reduction of pioglitazone-treated U937 cell adhesion to HU-
VEC was observed at concentrations as low as 10 Wmol/l of
pioglitazone (control 21.8S 4.64% adhesion, 0.5 Wmol/l
20.0 S 2.89%, 10 Wmol/l 8.45S 1.15% and 20 Wmol/l
8.10S 1.82%). Since we did not detect signi¢cant cellular dam-
age caused by these pioglitazone treatments using trypan blue
staining (data not shown), we chose to treat the U937 cells
with 20 Wmol/l of pioglitazone in the following experiments.
The inhibitory e¡ects of pioglitazone on the adhesion of U937
cells to HUVEC were then examined under £ow conditions at
a laminar shear stress level of 1.0 dyne/cm2. U937 cells were
incubated in the presence of 20 Wmol/l of pioglitazone for 48 h
then perfused over HUVEC for 10 min. As shown in Fig. 1B,
the adhesion, but not rolling, of U937 cells was signi¢cantly
reduced after pioglitazone treatment (control 8.20 S 3.03 cells/
HPF (high power ¢eld); pioglitazone 2.40 S 1.67 cells/HPF,
P6 0.006).
3.2. E¡ect of pioglitazone on integrin expression in U937 cells
To elucidate the molecular mechanism of the pioglitazone-
induced reduction of U937 cell adhesion, cell surface integrin
expression after pioglitazone treatment was examined by £ow
cytometric analysis. The expression levels of CD11a, CD18,
and CD49d on U937 cells were not signi¢cantly a¡ected after
treatment, as shown in Fig. 2A.
3.3. Pioglitazone reduced actin polymerization and RhoA
activation in U937 cells
We then examined the e¡ect of pioglitazone on the cyto-
skeletal network in U937 cells by detecting F-actin, which
re£ects actin polymerization. When U937 cells were incubated
with 20 Wmol/l of pioglitazone for 48 h, the F-actin content in
U937 cells was signi¢cantly decreased (0.64-fold of control,
P6 0.05) (Fig. 2B). The e¡ect of pioglitazone on RhoA
GTPase activity in U937 cells was also examined by determin-
ing RhoA translocation from the cytoplasm to membrane and
Rho pull-down assay using a GST fusion protein of the Rho
e¡ector Rhotekin. Western blotting analysis revealed that the
expression of RhoA protein in the membrane fraction and
Rhotekin-bound activated RhoA were signi¢cantly decreased
in U937 cells after pioglitazone treatment (Fig. 2C).
Fig. 1. E¡ect of pioglitazone on adhesion of U937 cells to HUVEC
under static and physiological £ow conditions. A: U937 cells
(1U106/ml) were incubated with the indicated amounts of pioglita-
zone for 48 h and then placed on HUVEC activated with 10 U/ml
of IL-1L for 4 h. An adhesion assay was carried out as described in
Section 2. B: U937 cells were treated with (+) or without (3) 20
Wmol/l of pioglitazone for 48 h and then perfused over activated
HUVEC monolayers at a £ow rate of 1.0 dyne/cm2. Rolling and
adherent U937 cells on HUVEC were counted in 10 di¡erent 20U
microscope ¢elds as described in Section 2. Data are representative
of three separate observations.
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3.4. Pioglitazone inhibited FAK activation in U937 cells
We also investigated the involvement of FAK in U937 cells.
Western blotting analysis was carried out using antibodies to
detect phosphorylation of FAK at two distinct tyrosines. As
shown in Fig. 3A, the expression of total FAK was not af-
fected by pioglitazone treatment, however, FAK phosphory-
lation at tyrosine 925 was signi¢cantly inhibited. In contrast,
phosphorylation of FAK at tyrosine 397 was not a¡ected by
pioglitazone treatment.
3.5. PPAR antagonist failed to reverse the inhibitory e¡ects of
pioglitazone toward the adhesion of U937 cells to HUVEC
To examine whether the antagonizing PPARQ receptor has
some e¡ects on U937 adhesion, U937 cells were treated with
prostaglandin F2K (PGF2K) for 30 min prior to pioglitazone
treatment, in order to compete with the PPARQ binding of
pioglitazone. When adhesion assays were carried out, pre-
treatment of U937 cells with PGF2K failed to reverse the in-
hibitory e¡ects of pioglitazone toward the adhesion of U937
cells to the HUVEC monolayer (Fig. 3B).
4. Discussion
Recent studies have shown that TZDs have protective ef-
Fig. 2. E¡ect of pioglitazone on integrin expression, actin cytoskele-
ton, and RhoA GTPase in U937 cells. A: U937 cells (1U106/ml)
were incubated with 20 Wmol/l of pioglitazone (+) or medium alone
(3) for 48 h. Integrin expression in U937 cells was analyzed by
£ow cytometry analysis using monoclonal antibodies to integrins
(CD11a, CD18, VLA4) and compared to positive control HLA class
I (w6/32). Five thousand cells were analyzed for each condition.
Data are representative of four similar experiments. B: U937 cells
(1U106/ml) were incubated with 20 Wmol/l of pioglitazone or in me-
dium alone (control) for 48 h. F-actin content in U937 cells was de-
tected with phalloidin and quantitated using a £uorescent plate
reader as described in Section 2, and then expressed as a percentage
of that of the control. *P6 0.05 vs. control. Data are representative
of three separate observations. C: U937 cells were incubated with
medium alone (3) or 20 Wmol/l of pioglitazone (+) for 48 h. West-
ern blotting detected RhoA expression in the membrane and total
lysate of U937 cells for each condition. RhoA activity was also de-
termined using the Rhotekin assay. Blots are representative of three
separate experiments.
Fig. 3. A: E¡ects of pioglitazone on FAK activation in U937 cells.
U937 cells (1U106/ml) were incubated with 20 Wmol/l of pioglita-
zone (+) or in medium alone (3) for 48 h. The expressions of
pFAK (397Y), pFAK (925Y), and FAK were detected in each con-
dition by Western blotting analysis. Blots are representative of ¢ve
separate experiments. B: E¡ect of PPAR antagonist on adhesion of
U937 cells to HUVEC. U937 cells (1U106/ml) were incubated with
20 Wmol/l of pioglitazone, PGF2K, for 30 min prior to incubation
with 20 Wmol/l of pioglitazone, or medium alone for 48 h, and then
placed on HUVEC. An adhesion assay was carried out as described
in Section 2.
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fects against atherosclerosis, as well as direct biological e¡ects
on monocytes, vascular endothelium, and vascular smooth
muscle cells [10^12]. The present ¢ndings demonstrated that
preincubation of monocytes with pioglitazone, a TZD, signi¢-
cantly reduced monocytic U937 adhesion to activated HU-
VEC under both static and £ow conditions. Based on the
results of £ow cytometric analysis, pioglitazone did not have
an e¡ect on the expression levels of cell surface integrins in
U937 cells. In parallel with this observation, recent reports
have demonstrated that the surface expression levels of integ-
rins do not exclusively modulate the adhesive interactions of
leukocytes [13]. In the present experiments, we found a reduc-
tion of actin ¢lament after pioglitazone treatment. Further, it
has been reported that the actin cytoskeleton that is anchored
to focal adhesion sites is critically important in monocyte
adhesion to vascular endothelium [14], therefore, modulation
of the cytoskeletal network leads to an increase or decrease of
adhesive interactions. Pioglitazone signi¢cantly decreased the
¢lamentous actin contents in U937 cells and the RhoA activ-
ity. This e¡ect on RhoA inactivation and cytoskeletal modu-
lation may show a novel intracellular mechanism by which
pioglitazone inhibits monocyte adhesion. FAK is known to
regulate cell adhesion and migration in various cell types,
including non-adherent blood cells, by transferring signals to
integrins at the cellular adhesion site [15]. Further, we showed
that the phosphorylation of 925Y, which is reported to be
associated with the Ras/mitogen-activated protein kinase
pathway [16] was reduced by pioglitazone treatment. These
data suggest that dephosphorylation at 925Y may be involved
in the pioglitazone-mediated reduced adhesion of U937 cells.
In contrast, the total amount of FAK and phosphorylation of
FAK at tyrosine 397 was not a¡ected by pioglitazone treat-
ment. Interestingly, the PPARQ antagonist PGF2K failed to
cancel the pioglitazone-mediated reduction of U937 cell adhe-
sion, which implies that the observed phenomena occur inde-
pendently of PPARQ agonistic stimulation. In agreement with
our study, PPARQ-independent e¡ects of PPARQ ligands were
reported using TZDs [17]. Besides its activity as an agonist of
PPARQ, pioglitazone may suppress the activation of RhoA
GTPase. Careful examination in the future will be required
to elucidate the responsible molecular mechanisms and other
intracellular signaling important in cell adhesion. In summary,
we demonstrated that pioglitazone, a novel antidiabetic agent,
reduced IL-1L-induced monocyte adhesion to vascular endo-
thelium, actin polymerization, and FAK activation. A reduc-
tion of RhoA GTPase activations may be involved in this
process. Thus, in patients with diabetes, administration of
pioglitazone is bene¢cial in reducing the serum level of glucose
itself and may have clinical merits for modulating monocyte^
endothelial interaction.
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